Opportunity Information: Apply for RFA AG 24 001
The Alzheimer’s Disease Research Centers (ADRC) program (RFA-AG-24-001) is a National Institutes of Health (NIH) grant opportunity run by the National Institute on Aging (NIA) to support institutions that want to establish a new ADRC or renew an existing one. These awards use the P30 center grant mechanism and are specifically labeled “Clinical Trial Not Allowed,” meaning the center award itself is not intended to run clinical trials as part of the funded activities under this announcement. The overall purpose is to strengthen a nationwide network of major medical and research institutions that function as shared, national resources for Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) research, and to accelerate the translation of scientific progress into better diagnosis, care practices, and ultimately strategies to treat and possibly prevent AD/ADRD.
At a practical level, the FOA is aimed at building or sustaining comprehensive, coordinated research centers rather than isolated projects. An ADRC is expected to bring together multidisciplinary expertise, infrastructure, and shared resources that enable investigators to conduct high-quality AD/ADRD research efficiently and collaboratively. The announcement emphasizes that ADRCs are not meant to operate in isolation; they are expected to actively collaborate and coordinate with other NIH-funded programs and investigators, reinforcing the idea of a connected national network. This coordination aspect typically matters because AD/ADRD research relies on standardized approaches, shared data resources, harmonized clinical and research methods, and cross-site collaborations that make findings more comparable and broadly useful.
The program’s public health and translational focus is clear: NIA wants ADRCs to help move research advances into real-world impact. That includes improving diagnostic approaches and clinical care, supporting research that clarifies disease mechanisms and progression, and enabling studies that inform prevention or treatment strategies (even if the center grant itself does not support clinical trials). In other words, the center is intended to be a platform that supports a broad range of AD/ADRD research and helps discoveries travel the full path from scientific insight to improved patient and caregiver outcomes.
Eligibility is broad and spans many organization types across the United States, including state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and certain tribal organizations; independent school districts; special district governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly calls out several categories of institutions and organizations as eligible, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI), along with faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. While many U.S.-based entities can apply, non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. However, “foreign components,” as defined by the NIH Grants Policy Statement, are allowed, which typically means certain parts of the work may be conducted abroad under NIH rules when justified, even though the applicant organization itself must be U.S.-eligible.
This is a discretionary grant in the health funding category under CFDA 93.866. The original closing date listed is 2025-09-26. The posted award ceiling is $2,925,000. The FOA was created on 2023-01-11. Taken together, the opportunity is designed for institutions capable of running a mature, coordinated center-level effort that supports and connects investigators, resources, and collaborative research activity focused on AD and ADRD, while aligning with NIH expectations for national coordination, infrastructure-building, and translation of research into better clinical understanding and care.Apply for RFA AG 24 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2023-01-11.
- Applicants must submit their applications by 2025-09-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $2,925,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Alzheimer’s Disease Research Centers (ADRC) Program (RFA-AG-24-001)
What is this funding opportunity?
This opportunity is the Alzheimer’s Disease Research Centers (ADRC) program (RFA-AG-24-001), a National Institutes of Health (NIH) grant funding announcement run by the National Institute on Aging (NIA). It supports institutions that want to establish a new ADRC or renew an existing ADRC.
Which NIH institute is sponsoring the ADRC program under this announcement?
The National Institute on Aging (NIA), which is part of the NIH, is the sponsoring institute for this ADRC funding opportunity.
What grant mechanism is used for ADRC awards under this FOA?
The announcement uses the P30 center grant mechanism. In practice, this mechanism is used to support shared infrastructure and coordinated center-level resources rather than isolated, standalone research projects.
Is this FOA intended to fund clinical trials?
No. The FOA is explicitly labeled “Clinical Trial Not Allowed,” meaning the center award itself is not intended to run clinical trials as part of the funded activities under this announcement.
If clinical trials are not allowed, what is the center award meant to support?
The center award is intended to support a comprehensive, coordinated research center that brings together multidisciplinary expertise, infrastructure, and shared resources to enable high-quality Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) research efficiently and collaboratively.
What is the overall purpose of the ADRC program?
The overall purpose is to strengthen a nationwide network of major medical and research institutions that function as shared, national resources for AD/ADRD research and to accelerate translation of scientific progress into better diagnosis, care practices, and ultimately strategies to treat and possibly prevent AD/ADRD.
Is the ADRC program focused on individual projects or on building a coordinated center?
This FOA is aimed at building or sustaining comprehensive, coordinated research centers rather than isolated projects. The expectation is that the ADRC functions as a platform that supports a broad range of AD/ADRD research activities.
Do ADRCs need to collaborate with other programs or centers?
Yes. The announcement emphasizes that ADRCs are not meant to operate in isolation. They are expected to actively collaborate and coordinate with other NIH-funded programs and investigators as part of a connected national network.
Why is coordination across centers and programs emphasized?
Coordination matters because AD/ADRD research often depends on standardized approaches, shared data resources, harmonized clinical and research methods, and cross-site collaborations that make findings more comparable and broadly useful across the national research community.
What research areas or outcomes is NIA trying to advance through ADRCs?
The FOA highlights a public health and translational focus. ADRCs are expected to help move research advances into real-world impact, including improving diagnostic approaches and clinical care, supporting research that clarifies disease mechanisms and progression, and enabling studies that inform prevention or treatment strategies (even though the center award itself does not support clinical trials).
Who is eligible to apply?
Eligibility is broad across the United States. Eligible applicants include state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and certain tribal organizations; independent school districts; special district governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.
Are specific types of institutions explicitly identified as eligible?
Yes. The FOA explicitly identifies multiple categories as eligible, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI). It also calls out faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Can a non-U.S. (foreign) institution apply as the applicant organization?
No. Non-U.S. (foreign) institutions are not eligible to apply under this FOA.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible under this announcement.
Are any international activities allowed at all?
Yes. While the applicant organization must be U.S.-eligible, “foreign components” (as defined by the NIH Grants Policy Statement) are allowed. This typically means certain justified parts of the work may be conducted abroad under NIH rules, even though the applicant cannot be a foreign institution.
What type of grant is this and what is the funding category?
This is a discretionary grant in the health funding category.
What is the CFDA number listed for this opportunity?
The CFDA number listed is 93.866.
What is the listed application closing date?
The original closing date listed for this opportunity is 2025-09-26.
What is the award ceiling shown in the opportunity details?
The posted award ceiling is $2,925,000.
When was this FOA created?
The FOA was created on 2023-01-11.
What kinds of institutions is this opportunity best suited for?
Based on the description provided, this opportunity is designed for institutions capable of running a mature, coordinated center-level effort: bringing together multidisciplinary expertise, maintaining shared research infrastructure and resources, and participating in national coordination and collaboration related to AD/ADRD research.
What does it mean that ADRCs function as “shared, national resources”?
It means the ADRCs are intended to contribute to a nationwide network where infrastructure, expertise, and research-enabling resources support not only local investigators but also collaborative work across the broader AD/ADRD research community.
Does this FOA support work aimed at improving patient and caregiver outcomes?
Yes. The FOA’s translational focus includes moving discoveries toward improved diagnosis and care practices, with the long-term aim of advancing strategies to treat and possibly prevent AD/ADRD, thereby improving outcomes for patients and caregivers.
Browse more opportunities from the same category: Health
Next opportunity: NEA Research Grants in the Arts, FY2024
Previous opportunity: Social Psychology
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 24 001
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 24 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) Apply for PAR 23 084 Funding Number: PAR 23 084 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional) Apply for PAR 23 101 Funding Number: PAR 23 101 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) Apply for PAR 23 087 Funding Number: PAR 23 087 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required) Apply for RFA MH 23 170 Funding Number: RFA MH 23 170 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) Apply for PAR 23 105 Funding Number: PAR 23 105 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) Apply for PAR 23 102 Funding Number: PAR 23 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required ) Apply for PAR 23 103 Funding Number: PAR 23 103 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| PROPEL Youth and Gender (Round 3): Promoting Results and Outcomes through Policy and Economic Levers Apply for 7200AA22APS00002 03 Funding Number: 7200AA22APS00002 03 Agency: Agency for International Development Category: Health Funding Amount: $20,000,000 |
| AHRQ Small Research Projects to Advance the Science of Primary Care (R03) Apply for PA 23 115 Funding Number: PA 23 115 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) Apply for RFA MD 23 002 Funding Number: RFA MD 23 002 Agency: National Institutes of Health Category: Health Funding Amount: $295,924 |
| Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed) Apply for PAR 22 262 Funding Number: PAR 22 262 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed) Apply for RFA AG 24 018 Funding Number: RFA AG 24 018 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61/R33 Clinical Trial Not Allowed) Apply for PAR 23 089 Funding Number: PAR 23 089 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integrated Social and Behavior Change Apply for RFI 72052123R00004 Funding Number: RFI 72052123R00004 Agency: Haiti USAID-Port Au Prince Category: Health Funding Amount: Case Dependent |
| Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional) Apply for RFA EB 23 001 Funding Number: RFA EB 23 001 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Comprehensive Community Prevention and Continuum of Care (C4) Project Apply for RFI 674 23 COMPREHENSIVECAREBOTS Funding Number: RFI 674 23 COMPREHENSIVECAREBOTS Agency: South Africa USAID-Pretoria Category: Health Funding Amount: Case Dependent |
| NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) Apply for PAR 23 111 Funding Number: PAR 23 111 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional) Apply for PAR 23 077 Funding Number: PAR 23 077 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Apply for PAR 23 035 Funding Number: PAR 23 035 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consortium for Food Allergy Research: Leadership Center (UM1 Clinical Trial Required) Apply for RFA AI 22 077 Funding Number: RFA AI 22 077 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 24 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.